Please login to the form below
Gleevec/Glivec
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gleevec/Glivec was produced by Novartis.
GSK raises stake in Indian subsidiary
Arguably more worrying for research-oriented multinationals has been a series of decisions that have removed IP protection in India for drugs such as Novartis' Glivec (imatinib), Roche's Herceptin (trastuzumab)
Pharma slammed for undermining South African IP reforms
Citing the case of Novartis' cancer drug Glivec (imatinib) - which has been the subject of an IP battleground in India in recent years - the NGO says the drug costs 35 times
Novartis cancer chief Hoppenot leaves for top job at Incyte
that could see the loss of patent protection on $4.7bn cancer blockbuster Glivec (imatinib).
Novartis' Tasigna tops Glivec in long-term trial
residual disease who switched to Tasigna after long-term treatment with Glivec, and Glivec non-responders. ... occur with Tasigna than Glivec by the end of the follow-up period.
Pharma should not ignore India
With specific reference to Novartis' Glivec, the Indian Supreme Court ruled that, in its view, there was no new invention and no new substance used in the drug. ... innovation? To be clear, this is not the issue that resulted in the denial of patents in
[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
